Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Geert D'Haens; Severine Vermeire; Guy Lambrecht; Filip Baert; Peter Bossuyt; Benjamin Pariente; Anthony Buisson; Yoram Bouhnik; Jerome Filippi; Janneke Vander Woude; Philippe Van Hootegem; Jacques Moreau; Edouard Louis; Denis Franchimont; Martine De Vos; Fazia Mana; Laurent Peyrin-Biroulet; Hedia Brixi; Matthieu Allez; Philip Caenepeel; Alexandre Aubourg; Bas Oldenburg; Marieke Pierik; Ann Gils; Sylvie Chevret; David Laharie; GETAID

doi:10.1053/j.gastro.2018.01.004

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Geert D'Haens, Severine Vermeire, Guy Lambrecht, Filip Baert, Peter Bossuyt, Benjamin Pariente, Anthony Buisson, Yoram Bouhnik, Jerome Filippi, Janneke Vander Woude, Philippe Van Hootegem, Jacques Moreau, Edouard Louis, Denis Franchimont, Martine De Vos, Fazia Mana, Laurent Peyrin-Biroulet, Hedia Brixi, Matthieu Allez, Philip CaenepeelAlexandre Aubourg, Bas Oldenburg, Marieke Pierik, Ann Gils, Sylvie Chevret, David Laharie, GETAID

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1343-1351.e1
Number of pages	10
Journal	Gastroenterology
Volume	154
Issue number	5
DOIs	https://doi.org/10.1053/j.gastro.2018.01.004
Publication status	Published - 1 Apr 2018

Keywords

Crohn's Disease
Therapeutic Drug Monitoring
Infliximab
Mucosal Healing
INFLAMMATORY-BOWEL-DISEASE
SCHEDULED MAINTENANCE TREATMENT
RANDOMIZED-TRIAL
TROUGH LEVEL
ANTIBODIES
THERAPY
INTENSIFICATION
MULTICENTER
OUTCOMES

Access to Document

10.1053/j.gastro.2018.01.004

Cite this

D'Haens, G., Vermeire, S., Lambrecht, G., Baert, F., Bossuyt, P., Pariente, B., Buisson, A., Bouhnik, Y., Filippi, J., Vander Woude, J., Van Hootegem, P., Moreau, J., Louis, E., Franchimont, D., De Vos, M., Mana, F., Peyrin-Biroulet, L., Brixi, H., Allez, M., ... GETAID (2018). Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology, 154(5), 1343-1351.e1. https://doi.org/10.1053/j.gastro.2018.01.004

D'Haens, Geert ; Vermeire, Severine ; Lambrecht, Guy ; Baert, Filip ; Bossuyt, Peter ; Pariente, Benjamin ; Buisson, Anthony ; Bouhnik, Yoram ; Filippi, Jerome ; Vander Woude, Janneke ; Van Hootegem, Philippe ; Moreau, Jacques ; Louis, Edouard ; Franchimont, Denis ; De Vos, Martine ; Mana, Fazia ; Peyrin-Biroulet, Laurent ; Brixi, Hedia ; Allez, Matthieu ; Caenepeel, Philip ; Aubourg, Alexandre ; Oldenburg, Bas ; Pierik, Marieke ; Gils, Ann ; Chevret, Sylvie ; Laharie, David ; GETAID. / Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. In: Gastroenterology. 2018 ; Vol. 154, No. 5. pp. 1343-1351.e1.

@article{3d823eb8e91b44798e02a672c551207a,

title = "Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease",

keywords = "Crohn's Disease, Therapeutic Drug Monitoring, Infliximab, Mucosal Healing, INFLAMMATORY-BOWEL-DISEASE, SCHEDULED MAINTENANCE TREATMENT, RANDOMIZED-TRIAL, TROUGH LEVEL, ANTIBODIES, THERAPY, INTENSIFICATION, MULTICENTER, OUTCOMES",

author = "Geert D'Haens and Severine Vermeire and Guy Lambrecht and Filip Baert and Peter Bossuyt and Benjamin Pariente and Anthony Buisson and Yoram Bouhnik and Jerome Filippi and {Vander Woude}, Janneke and {Van Hootegem}, Philippe and Jacques Moreau and Edouard Louis and Denis Franchimont and {De Vos}, Martine and Fazia Mana and Laurent Peyrin-Biroulet and Hedia Brixi and Matthieu Allez and Philip Caenepeel and Alexandre Aubourg and Bas Oldenburg and Marieke Pierik and Ann Gils and Sylvie Chevret and David Laharie and GETAID",

year = "2018",

month = apr,

day = "1",

doi = "10.1053/j.gastro.2018.01.004",

language = "English",

volume = "154",

pages = "1343--1351.e1",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "Elsevier Saunders",

number = "5",

}

D'Haens, G, Vermeire, S, Lambrecht, G, Baert, F, Bossuyt, P, Pariente, B, Buisson, A, Bouhnik, Y, Filippi, J, Vander Woude, J, Van Hootegem, P, Moreau, J, Louis, E, Franchimont, D, De Vos, M, Mana, F, Peyrin-Biroulet, L, Brixi, H, Allez, M, Caenepeel, P, Aubourg, A, Oldenburg, B, Pierik, M, Gils, A, Chevret, S, Laharie, D & GETAID 2018, 'Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease', Gastroenterology, vol. 154, no. 5, pp. 1343-1351.e1. https://doi.org/10.1053/j.gastro.2018.01.004

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. / D'Haens, Geert; Vermeire, Severine; Lambrecht, Guy; Baert, Filip; Bossuyt, Peter; Pariente, Benjamin; Buisson, Anthony; Bouhnik, Yoram; Filippi, Jerome; Vander Woude, Janneke; Van Hootegem, Philippe; Moreau, Jacques; Louis, Edouard; Franchimont, Denis; De Vos, Martine; Mana, Fazia; Peyrin-Biroulet, Laurent; Brixi, Hedia; Allez, Matthieu; Caenepeel, Philip; Aubourg, Alexandre; Oldenburg, Bas; Pierik, Marieke; Gils, Ann; Chevret, Sylvie; Laharie, David; GETAID.

In: Gastroenterology, Vol. 154, No. 5, 01.04.2018, p. 1343-1351.e1.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

AU - D'Haens, Geert

AU - Vermeire, Severine

AU - Lambrecht, Guy

AU - Baert, Filip

AU - Bossuyt, Peter

AU - Pariente, Benjamin

AU - Buisson, Anthony

AU - Bouhnik, Yoram

AU - Filippi, Jerome

AU - Vander Woude, Janneke

AU - Van Hootegem, Philippe

AU - Moreau, Jacques

AU - Louis, Edouard

AU - Franchimont, Denis

AU - De Vos, Martine

AU - Mana, Fazia

AU - Peyrin-Biroulet, Laurent

AU - Brixi, Hedia

AU - Allez, Matthieu

AU - Caenepeel, Philip

AU - Aubourg, Alexandre

AU - Oldenburg, Bas

AU - Pierik, Marieke

AU - Gils, Ann

AU - Chevret, Sylvie

AU - Laharie, David

AU - GETAID

PY - 2018/4/1

Y1 - 2018/4/1

KW - Crohn's Disease

KW - Therapeutic Drug Monitoring

KW - Infliximab

KW - Mucosal Healing

KW - INFLAMMATORY-BOWEL-DISEASE

KW - SCHEDULED MAINTENANCE TREATMENT

KW - RANDOMIZED-TRIAL

KW - TROUGH LEVEL

KW - ANTIBODIES

KW - THERAPY

KW - INTENSIFICATION

KW - MULTICENTER

KW - OUTCOMES

U2 - 10.1053/j.gastro.2018.01.004

DO - 10.1053/j.gastro.2018.01.004

M3 - Article

VL - 154

SP - 1343-1351.e1

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -

D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 Apr 1;154(5):1343-1351.e1. https://doi.org/10.1053/j.gastro.2018.01.004